Study guide
9.1 Patient-Specific Parameters: Verifying CSP Orders
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
9.1 Patient-Specific Parameters: Verifying CSP Orders
Key Takeaways Explain This Topic AI
Order verification for a CSP checks the indication, dose basis (actual, ideal or adjusted weight, or body surface area), organ function, age, allergies, fluid limits, laboratory values, vascular access and route before compounding starts.
The Cockcroft-Gault equation estimates creatinine clearance as (140 - age) × weight ÷ (72 × serum creatinine), multiplied by 0.85 for females, and it drives renal dose adjustment.
The Mosteller body surface area formula, √(height in cm × weight in kg ÷ 3600), underlies most chemotherapy dosing, and a BCSCP should recalculate BSA-based doses independently.
For patients at risk of refeeding syndrome, ASPEN's 2020 consensus advises starting nutrition cautiously (about 100-150 g dextrose or 10-20 kcal/kg in the first 24 hours), giving thiamine 100 mg before feeding, and monitoring potassium, magnesium and phosphorus closely.
Neonates need extra checks: no benzyl alcohol, aluminum limits (at most 25 µg/L in large-volume PN components), tight calcium-phosphate limits and syringes sized for tiny volumes.
Last updated: September 2026
9.1 Patient-Specific Parameters: Verifying CSP Orders
A sterile preparation can be perfectly aseptic and still harm the patient if it is the wrong dose, too concentrated for the vein, or unsafe for that patient's kidneys, age or allergies. Domain 2 of the BCSCP outline begins with patient-specific parameters (task 2A1): laboratory values, disease state, age, pathophysiology, anatomy and pharmacology. The sterile compounding pharmacist is the last clinical check before a CSP is made, so order review has to be systematic.
A systematic order-review checklist
- Parameter What to check Example CSP issue
- Indication and drug Right drug for the diagnosis; therapeutic duplication Two anticoagulant infusions ordered
Dose basis Actual, ideal or adjusted body weight; BSA; fixed dose Aminoglycoside dosed on total body weight in obesity
Renal function Creatinine clearance or eGFR; dialysis Vancomycin, acyclovir, electrolytes in PN
Hepatic function Bilirubin, transaminases, INR Taxane or anthracycline dose reductions; PN-associated liver disease
Age Neonates (immature metabolism, excipient toxicity); older adults (lower clearance) Benzyl alcohol-preserved flushes in neonates
Laboratory values K, Mg, phosphate, Ca, Na, glucose, triglycerides, blood counts PN potassium when the serum level is 5.6 mmol/L
Fluid status Fluid restriction; heart or kidney failure Concentrate the infusion within stability and access limits
Allergies and sensitivities Drug allergies; latex; preservatives; egg or soy (lipid emulsions) Soybean-oil lipid emulsion in a patient with a soy protein allergy
Pregnancy and lactation Teratogenic HDs; dose changes Handling and counseling for reproductive-risk HDs
Access and route Peripheral or central line; intrathecal or epidural 1,300 mOsm/L PN ordered for a peripheral line
Co-infusions Y-site compatibility with other running infusions Phenytoin with dextrose; ceftriaxone with calcium in neonates
BPS gives no reference range table on the exam, so know common normal ranges. Laboratory values appear in the SI units used in U.S. practice.
Renal function: Cockcroft-Gault CrCl (mL/min) = ( 140 − age ) × weight (kg) 72 × SCr (mg/dL) × 0.85 (if female) \text{CrCl (mL/min)} = \frac{(140 - \text{age}) \times \text{weight (kg)}}{72 \times \text{SCr (mg/dL)}} \times 0.85 \text{ (if female)} CrCl (mL/min) = 72 × SCr (mg/dL) ( 140 − age ) × weight (kg) × 0.85 (if female)
Worked example: A 70-year-old woman weighing 60 kg has a serum creatinine of 1.2 mg/dL. CrCl = ( 140 − 70 ) × 60 72 × 1.2 × 0.85 = 4200 86.4 × 0.85 ≈ 41 mL/min \text{CrCl} = \frac{(140 - 70) \times 60}{72 \times 1.2} \times 0.85 = \frac{4200}{86.4} \times 0.85 \approx 41 \text{ mL/min} CrCl = 72 × 1.2 ( 140 − 70 ) × 60 × 0.85 = 86.4 4200 × 0.85 ≈ 41 mL/min
Many renally cleared antimicrobials need an interval or dose change at this level. Check the product labeling or an institutional renal-dosing table.
Weight choices
Ideal body weight (IBW): men 50 + 2.3 × 50 + 2.3 \times 50 + 2.3 × (inches over 60); women 45.5 + 2.3 × 45.5 + 2.3 \times 45.5 + 2.3 × (inches over 60), in kg.
Adjusted body weight (AdjBW): IBW + 0.4 × ( TBW − IBW ) \text{IBW} + 0.4 \times (\text{TBW} - \text{IBW}) IBW + 0.4 × ( TBW − IBW ) . It is often used for aminoglycosides in obesity.
Total body weight (TBW): used for some drugs, such as many vancomycin loading doses, according to guidelines.
Body surface area (BSA) for chemotherapy BSA (m 2 ) = height (cm) × weight (kg) 3600 \text{BSA (m}^2\text{)} = \sqrt{\frac{\text{height (cm)} \times \text{weight (kg)}}{3600}} BSA (m 2 ) = 3600 height (cm) × weight (kg)
For a patient 170 cm tall weighing 70 kg: 170 × 70 ÷ 3600 = 3.31 ≈ 1.82 m 2 \sqrt{170 \times 70 \div 3600} = \sqrt{3.31} \approx 1.82\,\text{m}^2 170 × 70 ÷ 3600 = 3.31 ≈ 1.82 m 2 . A dose of 75 mg/m² is therefore about 136 mg. Recalculate BSA-based doses independently and check them against the protocol, including any dose caps and cumulative limits, such as lifetime anthracycline exposure.
Parenteral nutrition order review
Macronutrients: Check dextrose (glucose infusion rate), amino acids (g/kg/day) and lipids (g/kg/day) against the patient's needs and guidelines. Check triglycerides before and during lipid therapy.
Electrolytes: Adjust to serum values and to losses such as diarrhea or fistula output, and keep calcium and phosphate within the solubility curve (see 8.3).
Refeeding syndrome: ASPEN's 2020 consensus on refeeding risk advises, for patients at risk:
start cautiously, around 100-150 g of dextrose or 10-20 kcal/kg in the first 24 hours, and advance over several days;
give thiamine 100 mg before feeding and daily for 5 to 7 days or longer;
check potassium, magnesium and phosphorus before starting and every 12 hours for the first 3 days in high-risk patients, replacing as needed.
Access: Peripheral PN is limited to about 900 mOsm/L. Higher concentrations need a central line (see 8.1).
Special populations
Neonates and infants:
Use preservative-free products and flushes, because benzyl alcohol can cause gasping syndrome.
FDA limits aluminum in large-volume parenterals used in PN to 25 µg/L or less and requires aluminum content on the labels of small-volume products.
Calcium-phosphate risk is high when amino acid concentrations are low.
Microvolumes need syringes sized to the volume (see 9.4).
Older adults: Lower clearance, lower muscle mass (serum creatinine can overestimate renal function), and a higher risk of fluid overload.
Pregnancy: Consider fetal risk from the therapy, and the handling risk for staff who are pregnant or planning pregnancy when HDs are involved. USP <800> requires staff of reproductive capability to confirm in writing that they understand the risks.
Pharmacology-based checks
Check for incompatible Y-site combinations , such as ceftriaxone with calcium-containing solutions in neonates. Check route-specific dose limits , since intrathecal doses are a small fraction of IV doses. Check dose caps , such as vincristine commonly capped at 2 mg per dose in adult protocols, and maximum infusion rates , such as potassium in peripheral lines under institutional policy.